Glenmark Life Sciences Q4 Results
- BSE: 543322
- NSE: GLS
- ISIN: INE03Q201024
- Sector: Biotechnology & Drugs
BSE
0.0
0.00 (0.00%)
0.00 (0.00%)Volume0.00
Updated: undefined NaN undefined, NaN | NaN:NaN:NaN
NSE
0.00.00 (0.00%)
0.00 (0.00%)Volume0.00
Updated: undefined NaN undefined, NaN | NaN:NaN:NaN
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Glenmark Life Sciences Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 24 | Dec 23 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Revenue | 536.60 | 572.80 | -6.32% | 536.60 | N/A |
| Selling/ General/ Admin Expenses Total | 72.26 | 71.05 | 1.69% | 72.26 | N/A |
| Depreciation/ Amortization | 14.53 | 13.18 | 10.30% | 14.53 | N/A |
| Other Operating Expenses Total | 84.20 | 87.00 | -3.23% | 84.20 | N/A |
| Total Operating Expense | 409.69 | 413.43 | -0.90% | 409.69 | N/A |
| Operating Income | 126.91 | 159.38 | -20.37% | 126.91 | N/A |
| Net Income Before Taxes | 129.68 | 160.68 | -19.30% | 129.68 | N/A |
| Net Income | 97.94 | 118.77 | -17.54% | 97.94 | N/A |
| Diluted Normalized EPS | 7.97 | 9.67 | -17.61% | 7.97 | N/A |